AbbVie Inc ABBV

NYSE US Health Care Biotechnology

$264.34 ▼ -0.29% ($-0.78)

Index member: S&P 500

Open $265.49

Prev Close $265.12

Day Range $262.59 – $266.00

52W Range $190.75 – $269.39

Market Cap $468.66B

P/E (TTM) 74.25

Beta 0.20

Div Yield 4.47%

EPS (TTM) $3.56

📋 Company Profile

Industry	Biotechnology
Sector	Health Care
Country	US
Exchange	NEW YORK STOCK EXCHANGE, INC.
Currency	USD
IPO Date	2013-01-02
Shares Out.	1,766,790,000
Website	abbvie.com/ ↗
Phone	13023513367
Employees	57,000
Revenue	$16.99B
Gross Profit	$12.70B
Net Income	$3.62B
Free Cash Flow	$18.21B
Total Assets	$135.12B
Total Liabilities	$141.00B
Equity	-$5.89B

About AbbVie Inc

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.

AbbVie Inc is a publicly traded company under the ticker symbol ABBV on the NEW YORK STOCK EXCHANGE, INC., operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.